Psychiatric disorders Archives

Latest Posts

Screenshot 2016 12 01 at 3.06.48 PM e1480601295300

News and Trends 2 Dec 2016

Mind, Mood and Microbes: Harnessing the Power of Probiotics

The canals of Amsterdam have attracted us this week to the capital of the Netherlands, where Winclove Probiotics has been working for more than 20 years in targeting the human…

December 2, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 30 Nov 2016

Drugging the Undruggable: New Acquisition to Boost GPCR Drugs

Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its pipeline and keep competitors in this profitable field at bay. Heptares Therapeutics develops therapies directed…

November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Oct 2016

World Mental Health Day: How is Biotech Helping the Cause?

Biotech is one of the main forces driving the development of effective therapies to treat neurological and mental disorders. For World Mental Health Day yesterday, we want to share with you some…

October 11, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

kings college depression biomarker diagnostic

News and Trends 14 Jun 2016

New Biomarkers could make Personalized Medicine for Depression

Researchers from King’s College London have succeeded in developing a blood test that can help choose the best treatment for depression patients - a big improvement over the current trial-and-error approach.…

June 14, 2016 - 3 minutesmins - By Denise Neves Gameiro

clinical depression glasgow ets6103 e therapeutics

News and Trends 16 Feb 2016

Sorry Scotland, Phase II Trial for Clinical Depression Fails against 55-Year Old Generic

I mean, Clinical depression is a tough indication for Biotech to tackle - particularly when facing off a '55-year old' generic (amitriptyline). But e-Therapeutics in Oxford (UK) has more to offer…

February 16, 2016 - 3 minutesmins - By Dani Bancroft

biogen alzheimer proteros rodin therapeutics atlas neurology

News and Trends 8 Jan 2016

Epigenetics Baby of Proteros is Signing Up with Top US Neurology Specialists

Founded in just 2013 by German Proteros and the US Atlas Ventures, Rodin Therapeutics is working epigenetics into discovery of novel therapies for Neurological diseases. Now they have hooked one…

January 8, 2016 - 3 minutesmins - By Dani Bancroft

brains imba cerebral organoids neurological disease

News and Trends 6 Jan 2016

Growing Mini-Brains in Labs to Better Understand Neurological Disease

Mini brains, about 3-4 mm are a breakthrough in Neurology which will enable researchers to study the development of neurological disease and perform drug tests ex vivo. Scientists from Institute…

January 6, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 10 May 2015

Succesful Phase III for Indivior’s Schizophrenia treatment

Indivior obtained top-line results from its phase III clinical trial of RBP-7000, a candidate treatment for schizophrenia. Based on these successful outcomes, the company expects to submit a New Drug…

May 10, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 2 May 2015

Newron raised new funds to continue the development of Neurological therapies

Newron Pharmaceuticals, a public company focused on novel Central Nervous System (CNS) and pain therapies, announces that it has completed a capital increase of approximately €23.2M (CHF24.3 million). This fundraising will be…

May 2, 2015 - 2 minutesmins - By Joachim Eeckhout

AOP Orphan Pharmaceuticals Confluence Pharmaceuticals Fragile X

News and Trends 23 Mar 2015

AOP Orphan and Confluence Pharmaceuticals, together for Fragile X Syndrome

AOP Orphan Pharmaceuticals and Confluence Pharmaceuticals, signed today a definitive agreement to co-develop and market Confluence’s lead asset, a product for the treatment of Fragile X Syndrome in Europe and…

March 23, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Mar 2015

Alkermes presents its new treatment of Alzheimer’s agitation

Alkermes reveals a new drug candidate, ALKS 7119, for treatment of Alzheimer’s agitation, depression and other central nervous system (CNS) diseases. Alkermes has successfully completed preclinical development and expects to…

March 4, 2015 - 2 minutesmins - By Lourdes Riquelme

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering